Journal article
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group
Kamala Thriemer, Albino Bobogare, Benedikt Ley, Clarice Samo Gudo, Mohammad Shafiul Alam, Nick M Anstey, Elizabeth Ashley, J Kevin Baird, Charlotte Gryseels, Elodie Jambert, Marcus Lacerda, Ferdinand Laihad, Jutta Marfurt, Ayodhia Pitaloka Pasaribu, Jeanne Rini Poespoprodjo, Inge Sutanto, Walter R Taylor, Christel van den Boogaard, Katherine E Battle, Lek Dysoley Show all
MALARIA JOURNAL | BMC | Published : 2018
Abstract
The goal to eliminate malaria from the Asia-Pacific by 2030 will require the safe and widespread delivery of effective radical cure of malaria. In October 2017, the Asia Pacific Malaria Elimination Network Vivax Working Group met to discuss the impediments to primaquine (PQ) radical cure, how these can be overcome and the methodological difficulties in assessing clinical effectiveness of radical cure. The salient discussions of this meeting which involved 110 representatives from 18 partner countries and 21 institutional partner organizations are reported. Context specific strategies to improve adherence are needed to increase understanding and awareness of PQ within affected communities; th..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Awarded by Department of Foreign Affairs and Trade (DFAT) - Australian Government
Awarded by OPRA - Bill & Melinda Gates Foundation
Awarded by NHMRC Research Fellowship
Awarded by MRC
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The meeting was funded through a grant from the Bill and Melinda Gates Foundation (OPP1164105) to the Asia Pacific Malaria Elimination Network (APMEN) Vivax Working Group (VxWG). The meeting was held in conjunction with the Malaria in Pregnancy Consortium (MiP) and back to back with the Medicines for Malaria Venture (MMV) stakeholder meeting who provided additional support for the meeting. Further support for the meeting was provided through a grant from the Department of Foreign Affairs and Trade (DFAT) supported by the Australian Government [Grant Agreement Number 72904]. KT, BL and JM are funded by the Asia Pacific Malaria Elimination Network (APMEN) and OPRA clinical trial funding, supported by the Bill & Melinda Gates Foundation (OPP1164105 and OPP1054404). NMA is supported by and NHMRC Research Fellowship (1135820).